Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Leukemia

  Free Subscription


Articles published in Hematol Oncol Clin North Am

Retrieve available abstracts of 25 articles:
HTML format



Single Articles


    August 2021
  1. BROWN JR
    Chronic Lymphocytic Leukemia: So Much Progress, Still Challenges Ahead.
    Hematol Oncol Clin North Am. 2021;35:xiii-xiv.
    PubMed    


  2. SHADMAN M, Maloney DG
    Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond.
    Hematol Oncol Clin North Am. 2021;35:847-862.
    PubMed     Abstract available


  3. SUN C, Wiestner A
    Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?
    Hematol Oncol Clin North Am. 2021;35:827-845.
    PubMed     Abstract available


  4. LAMPSON BL, Brown JR
    The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
    Hematol Oncol Clin North Am. 2021;35:807-826.
    PubMed     Abstract available


  5. THOMPSON MC, Mato AR
    Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
    Hematol Oncol Clin North Am. 2021;35:793-806.
    PubMed     Abstract available


  6. LASICA M, Tam CS
    Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib.
    Hematol Oncol Clin North Am. 2021;35:761-773.
    PubMed     Abstract available


  7. DING W
    The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and Beyond.
    Hematol Oncol Clin North Am. 2021;35:739-759.
    PubMed     Abstract available


  8. CHERNG HJ, Jain N
    First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?
    Hematol Oncol Clin North Am. 2021;35:725-738.
    PubMed     Abstract available


  9. VLACHONIKOLA E, Sofou E, Chatzidimitriou A, Stamatopoulos K, et al
    The Significance of B-cell Receptor Stereotypy in Chronic Lymphocytic Leukemia: Biological and Clinical Implications.
    Hematol Oncol Clin North Am. 2021;35:687-702.
    PubMed     Abstract available


  10. NG A, Chiorazzi N
    Potential Relevance of B-cell Maturation Pathways in Defining the Cell(s) of Origin for Chronic Lymphocytic Leukemia.
    Hematol Oncol Clin North Am. 2021;35:665-685.
    PubMed     Abstract available


    May 2021
  11. AL-SAWAF O, Seymour JF, Kater AP, Fischer K, et al
    Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?
    Hematol Oncol Clin North Am. 2021 May 15. pii: S0889-8588(21)00039.
    PubMed     Abstract available


    April 2020
  12. WINER ES
    Secondary Acute Myeloid Leukemia: A Primary Challenge of Diagnosis and Treatment.
    Hematol Oncol Clin North Am. 2020;34:449-463.
    PubMed     Abstract available


  13. GARCIA JS
    Prospects for Venetoclax in Myelodysplastic Syndromes.
    Hematol Oncol Clin North Am. 2020;34:441-448.
    PubMed     Abstract available


    February 2020
  14. BALIGA S, Yock TI
    Pediatric Cancer.
    Hematol Oncol Clin North Am. 2020;34:143-159.
    PubMed     Abstract available


    August 2018
  15. SAVAGE SA, Walsh MF
    Myelodysplastic Syndrome, Acute Myeloid Leukemia, and Cancer Surveillance in Fanconi Anemia.
    Hematol Oncol Clin North Am. 2018;32:657-668.
    PubMed     Abstract available


  16. SCHAEFER EJ, Lindsley RC
    Significance of Clonal Mutations in Bone Marrow Failure and Inherited Myelodysplastic Syndrome/Acute Myeloid Leukemia Predisposition Syndromes.
    Hematol Oncol Clin North Am. 2018;32:643-655.
    PubMed     Abstract available


  17. MCREYNOLDS LJ, Calvo KR, Holland SM
    Germline GATA2 Mutation and Bone Marrow Failure.
    Hematol Oncol Clin North Am. 2018;32:713-728.
    PubMed     Abstract available


  18. SIEFF CA
    Introduction to Acquired and Inherited Bone Marrow Failure.
    Hematol Oncol Clin North Am. 2018;32:569-580.
    PubMed     Abstract available


    December 2017
  19. ROSE-INMAN H, Kuehl D
    Acute Leukemia.
    Hematol Oncol Clin North Am. 2017;31:1011-1028.
    PubMed     Abstract available


    August 2017
  20. GARCIA JS, Stone RM
    The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
    Hematol Oncol Clin North Am. 2017;31:663-680.
    PubMed     Abstract available


  21. PATEL AB, O'Hare T, Deininger MW
    Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.
    Hematol Oncol Clin North Am. 2017;31:589-612.
    PubMed     Abstract available


  22. RADICH JP, Mauro MJ
    Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia.
    Hematol Oncol Clin North Am. 2017;31:577-587.
    PubMed     Abstract available


  23. GHIAUR G, Levis M
    Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment.
    Hematol Oncol Clin North Am. 2017;31:681-692.
    PubMed     Abstract available


    April 2017
  24. SUD A, Dearden C
    T-cell Prolymphocytic Leukemia.
    Hematol Oncol Clin North Am. 2017;31:273-283.
    PubMed     Abstract available


  25. DITTUS C, Sloan JM
    Adult T-cell Leukemia/Lymphoma: A Problem Abroad and at Home.
    Hematol Oncol Clin North Am. 2017;31:255-272.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: